Caribou Biosciences (CRBU) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jun, 2026Opening remarks and agenda
Meeting called to order virtually, welcoming stockholders and outlining the agenda, including business items and a Q&A session at the end.
Attendance confirmed by invitation and registration, with stockholders able to submit questions online.
Board and executive committee updates
Board members, officers, and independent auditors introduced; roles for the meeting specified.
Inspector of Election and Secretary roles confirmed for meeting procedures.
Shareholder proposals
Four proposals presented: election of three Class II Directors, ratification of Deloitte as auditor, amendment for officer exculpation, and potential adjournment for further proxy solicitation.
Board recommended approval of all proposals except for additional nominations, which were closed.
Latest events from Caribou Biosciences
- Key CAR-T programs advance toward pivotal trials, with data and regulatory updates due this year.CRBU
Jefferies Global Healthcare Conference 20259 Jul 2026 - Off-the-shelf CAR-T pipeline advances with pivotal trials and autoimmune expansion, backed by strong cash reserves.CRBU
7th Annual Evercore ISI HealthCONx Conference9 Jul 2026 - Upcoming data on allogeneic cell therapies signal progress toward scalable, curative autoimmune treatments.CRBU
Citi's 2024 Global Healthcare Conference8 Jul 2026 - Vispa-cel and CB-011 advance off-the-shelf CAR T therapy with strong efficacy, safety, and access.CRBU
H.C. Wainwright 4th Annual Cell Therapy Virtual Conference30 Jun 2026 - CB-011 achieved high response rates and durable remissions with manageable safety in r/r myeloma.CRBU
Corporate presentation12 Jun 2026 - Key votes include director elections, auditor ratification, and officer exculpation amendment.CRBU
Proxy filing5 Jun 2026 - Pivotal-ready and phase I CAR T programs advance, with major data updates expected at EHA.CRBU
Jefferies Global Healthcare Conference 20264 Jun 2026 - Allogeneic CAR T programs show strong clinical progress and are advancing toward pivotal trials.CRBU
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Off-the-shelf CAR-T therapies show strong clinical promise and scalable commercial potential.CRBU
Bank of America Global Healthcare Conference 202613 May 2026